You are here
Phase 3 Trial of Becatecarin in Bile Duct Cancer Initiated
SOUTH SAN FRANCISCO, Calif., June 23 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced the initiation of the Phase 3 clinical trial of XL119 (becatecarin) as a potential treatment for patients with bile duct cancer. The Phase 3 trial will include approximately 60 centers in the United States, Canada and Europe and is designed to enroll up to 600 patients with inoperable bile duct tumors. The primary endpoint of the trial is survival, and the two-arm trial is designed to compare patients treated with XL119 to patients treated with 5-FU/leucovorin.
"The initiation of the Phase 3 trial of XL119 in bile duct cancer is an important milestone for Exelixis," said George A. Scangos, Ph.D., president and chief executive officer. "For the patients and families who are affected by bile duct cancer, and for whom there are no approved therapies, we are hopeful that XL119 may provide some benefit. We are gratified by the enthusiasm and commitment of clinical investigators in North America and in Europe to this clinical program. We intend to work closely with Covance, our drug development services coordinator, to conduct the Phase 3 clinical trial in a high quality and expeditious manner. We are also appreciative of the National Cancer Institute's interest in continuing to explore the utility of XL119 in other indications, as encouraging results from these independent exploratory trials could suggest further development activities that Exelixis could undertake for the compound."
Data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from the Phase 2 clinical trial of XL119 showed that patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with XL119 showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.e., patients with partial response or stable disease). The safety profile of the compound was manageable and was consistent with that previously observed in Phase 1 and 2 studies. At this meeting, data were also presented showing a survival benefit in patients with non-small cell lung cancer. Data presented at the 2004 ASCO meeting showed additional encouraging results from a Phase 2 trial in patients with refractory breast cancer. Taken together, these findings suggest that XL119 is an active anticancer agent that warrants further clinical study to assess its therapeutic benefit.
In March 2004, Exelixis was granted orphan drug designation for XL119 in bile duct cancer. Orphan drug status is granted to treatments for diseases that affect fewer than 200,000 people in the U.S. and provides the benefits of extended market exclusivity for seven years, tax credits of up to 50% of the qualified clinical trial expenses and a waiver of FDA user fees. The company may also consider applying for European orphan drug designation for XL119 following the commencement of the Phase 3 clinical trial in Europe. Based on market research, Exelixis estimates that the annual incidence of bile duct tumors in currently addressable markets is approximately 30,000 patients.
Source: Exelixis, Inc.